

# **STUDIES ON TUMOUR ACTIVE COMPOUNDS WITH MULTIPLE METAL CENTRES**

**HASSAN DAGHRIRI**

*A thesis submitted in fulfillment  
of the requirements for the degree of  
Doctor of Philosophy*



SCHOOL OF BIOMEDICAL SCIENCES,  
FACULTY OF HEALTH SCIENCES,  
University of Sydney, AUSTRALIA

December, 2003

## DECLARATION

I, the author of the thesis, declare that none of the material in this thesis has been previously submitted by me or any other candidate for any degree to this or any other university.

## **ACKNOWLEDGEMENTS**

First of all, I thank God Almighty for giving me the courage and ability to start and finish this thesis.

There are a number of people who have helped me during the course of my research; however, it is impossible to record all of them here. I hope that they accept my sincere thanks and appreciation. I find myself deeply indebted to some people that I have to mention their names.

I would like to express my deep gratitude and thanks to my supervisor Dr. Fazlul Huq, whose encouragement, scholastic guidance, valuable advice, constructive comments and suggestions for the improvement of the thesis have all been of inestimable value for the preparation of the thesis in its present form. I am greatly indebted to him.

I am indebted to my associate supervisor Dr. Philip Beale, whose comments and valuable advice were of great help to the development of the thesis.

My special thanks and appreciation go to my government for granting me a scholarship to carry on my higher studies and in return I'm so grateful for their help, support and concern during my studies.

I am indebted to Ms. Mei Zhang of RPAH, Sydney and Mr. David Lockwood of School Biomedical Sciences for their assistance. Special thanks are also due to my colleagues Dr. Zahed Hossain, Ahmed Abdullah, Jung Qing Yu, Ashraf Chowdhury, Mariam Bibi, Mohammad Farhad, Hasan Tayyem, Howard Cheng and Ahmed Alharby for their company and encouragement.

Last but not least, my greatest debt of gratitude and appreciation is to my wife, whose help, courage and support are behind my achievement. The support I received from her made my life easier and happier; I cannot imagine my life without her. I appreciate her forbearance and patience during the course of my research. I feel obliged to mention my children Osamah, Hind, Ali, and Anas who have shown a great sense of responsibility, understanding and courage. I will never forget the prayers of my parents back home, which have been a constant source of encouragement throughout my life. Special thanks are due to them as well.

# TABLE OF CONTENTS

<b>ABSTRACT</b> .....	viii
<b>LIST OF FIGURES</b> .....	x
<b>LIST OF TABLES</b> .....	xv
<b>ABBREVIATIONS</b> .....	xviii
Chapter One .....	1
1. <b>Literature review</b> .....	1
1.1. Introduction.....	1
1.1.1. Cancer .....	1
1.1.2. Causes of cancer .....	3
1.1.3. Treatment of cancer .....	4
1.1.3.1. Surgery.....	5
1.1.3.2. Radiation .....	5
1.1.3.3. Chemotherapy .....	6
1.1.4. Structure of DNA .....	8
1.1.5. Metals in chemotherapy.....	14
Chapter Two .....	19
2. <b>Platinum based anticancer drugs</b> .....	19
2.1. Cisplatin .....	20
2.1.1. Chemistry of cisplatin .....	21
2.1.2. Uses and limitations of cisplatin .....	27
2.1.2.1. Uses of cisplatin .....	28
2.1.2.2. Limitation of cisplatin .....	29
2.2. Second and third generation mononuclear platinum based anticancer drugs .....	33
2.2.1. Carboplatin.....	34
2.2.2. Cisplatin analogues .....	35
2.2.2.1. Nedaplatin (245-s).....	36
2.2.2.2. Tetraplatin (ormaplatin) .....	37
2.2.2.3. Oxaliplatin.....	37
2.2.2.4. Iproplatin .....	38
2.2.2.5. Enloplatin .....	39
2.2.2.6. Lobaplatin .....	39
2.2.3. Orally active platinum drugs.....	39
2.2.3.1. JM216.....	40
2.2.3.2. JM335.....	41
2.2.3.3. ZD0473 .....	42
2.2.3.4. C5-OHP-Cl.....	43
2.3. Multinuclear platinum compounds .....	44
2.3.1. Dinuclear platinum complexes.....	45
2.3.2. Trinuclear Pt(II) complexes .....	50

Chapter Three.....	58
3. <b>Experimental</b> .....	58
3.1. Syntheses of compounds .....	58
3.1.1. Materials .....	58
3.1.2. Preparation of transplatin and transpalladin.....	59
3.1.2.1. Preparation of transplatin .....	59
3.1.2.2. Preparation of transpalladin .....	59
3.1.3. Syntheses of trinuclear compounds .....	60
3.1.3.1. Preparation of DH6Cl.....	61
3.1.3.2. Preparation of DH4Cl.....	63
3.1.3.3. Preparation of DH5Cl.....	65
3.1.3.4. Preparation of DH7Cl.....	68
3.1.3.5. Preparation of DHD .....	69
3.2. Characterization of compounds .....	73
3.2.1. Microanalysis .....	73
3.2.2. Molar conductivity.....	82
3.2.3. Spectral studies .....	82
3.2.3.1. Infrared spectra .....	82
3.2.3.2. Raman spectra .....	83
3.2.3.3. Mass spectrometry.....	83
3.2.3.4. Nuclear magnetic resonance spectroscopy (NMR).....	84
3.3. Biological activity .....	85
3.3.1. Materials .....	85
3.3.1.1. Preparation of medium.....	86
3.3.1.2. Phosphate buffered saline (PBS) preparation.....	87
3.3.1.3. Trypsin preparation.....	87
3.3.1.4. Hepes preparation.....	88
3.3.1.5. Cells recovery from liquid nitrogen.....	88
3.3.1.6. Cell subculture .....	88
3.3.1.7. Cell count .....	89
3.3.1.8. Storage of the cell lines.....	90
3.3.2. MTT assay.....	90
3.3.3. Cytotoxicity.....	93
3.4. Cellular platinum uptake and DNA binding .....	94
3.4.1. Materials .....	94
3.4.2. Drug addition and cell treatment.....	95
3.4.3. Cell uptake .....	96
3.4.4. Platinum DNA binding .....	96
3.5. Interaction with DNA.....	98
3.5.1. Materials .....	98
3.5.1.1. Preparation of 50x TAE stock solution and TAE working solution buffers.....	99
3.5.1.2. Gel preparation.....	99
3.5.1.3. Salmon sperm DNA preparation.....	99
3.5.2. Interaction between pBR322 plasmid DNA and the hebronuclear complexes .....	100

3.5.2.1.	Interaction between compounds and pBR322 plasmid DNA: electrophoretic assay.....	103
3.5.2.2.	Interaction of compounds and pBR322 plasmid DNA in presence of BamH1 restriction enzyme digestion. ....	104
3.5.3.	Interaction with salmon sperm DNA.....	105
3.6.	Interaction between DH6Cl and nucleobases .....	106
3.6.1.	Materials .....	106
3.6.2.	HPLC method .....	107
3.6.3.	Binding ratio .....	107
Chapter Four	.....	108
4. <b>Results</b>	.....	108
4.1. Characterization of compounds	.....	108
4.1.1. Composition.....	108	
4.1.1.1. DH4Cl.....	108	
4.1.1.2. DH5Cl.....	109	
4.1.1.3. DH6Cl.....	110	
4.1.1.4. DH7Cl.....	111	
4.1.1.5. DHD .....	112	
4.1.1.6. DH1Cl.....	113	
4.1.2. Spectral studies .....	114	
4.1.2.1. IR, Raman, Mass and <sup>1</sup> H NMR spectra of DH4Cl .....	114	
4.1.2.2. IR, Raman, Mass and <sup>1</sup> H NMR spectra of DH5Cl .....	117	
4.1.2.3. IR, Raman, Mass and <sup>1</sup> H NMR spectra of DH6Cl .....	120	
4.1.2.4. IR, Raman, Mass and <sup>1</sup> H NMR spectra of DH7Cl .....	124	
4.1.2.5. IR, Raman, Mass and <sup>1</sup> H NMR spectra of DHD .....	127	
4.2. Cytotoxicity.....	131	
4.2.1. Activity summary.....	145	
4.3. Cell uptake and DNA binding.....	148	
4.3.1. Cell uptake .....	148	
4.3.2. DNA binding.....	154	
4.3.3. Gel electrophoresis.....	157	
4.3.3.1. Interaction with pBR322 plasmid DNA.....	157	
4.3.3.2. BamH1 digestion.....	159	
4.3.3.3. Interaction between the compounds and salmon sperm DNA (ssDNA) ...	163	
4.4. Interaction between DH6Cl and nucleobases .....	165	
4.4.1. HPLC .....	165	
4.4.2. Binding ratio .....	166	
Chapter Five	.....	169
5. <b>Discussion</b> .....	169	
5.1. Characterization of compounds .....	169	
5.1.1. Elemental analyses .....	170	
5.1.2. Spectral studies .....	171	
5.1.2.1. Interpretation of IR and Raman spectral data .....	171	
5.1.2.2. Mass and <sup>1</sup> H NMR spectral analyses .....	176	

5.2.	Activity of compounds.....	182
5.3.	Cell uptake and binding with DNA .....	186
5.3.1.	Cell uptake .....	187
5.3.1.1.	Platinum uptake.....	187
5.3.1.2.	Palladium uptake.....	192
5.3.2.	Platinum DNA binding .....	193
5.4.	Interaction with DNA and nucleobases .....	200
5.4.1.	Interaction with DNA.....	200
5.4.1.1.	Interaction with pBBR322 plasmid DNA .....	200
5.4.1.2.	BamH1 digestion.....	206
5.4.1.3.	Interaction with ssDNA .....	208
5.4.2.	Interaction between DH6Cl and nucleobases .....	209
Chapter Six.....		212
6.	<b>Conclusion</b> .....	212
<b>References</b> .....		218

## ABSTRACT

Four tumour active trinuclear complexes: DH4Cl:  $[\{trans\text{-PtCl(NH}_3)_2\}_2\mathbf{m}\{trans\text{-Pd(NH}_3)_2(\text{H}_2\text{N(CH}_2)_4\text{NH}_2)_2\}]\text{Cl}_4$ , DH5Cl:  $[\{trans\text{-PtCl(NH}_3)_2\}_2\mathbf{m}\{trans\text{-Pd(NH}_3)_2(\text{H}_2\text{N(CH}_2)_5\text{NH}_2)_2\}]\text{Cl}_4$ , DH6Cl:  $[\{trans\text{-PtCl(NH}_3)_2\}_2\mathbf{m}\{trans\text{-Pd(NH}_3)_2(\text{H}_2\text{N(CH}_2)_6\text{NH}_2)_2\}]\text{Cl}_4$ , DH7Cl:  $[\{trans\text{-PtCl(NH}_3)_2\}_2\mathbf{m}\{trans\text{-Pd(NH}_3)_2(\text{H}_2\text{N(CH}_2)_7\text{NH}_2)_2\}]\text{Cl}_4$  and one dinuclear complex DHD:  $[\{trans\text{-PtCl(NH}_3)_2\}_2\mu\text{-}\{trans\text{-PdCl(NH}_3)_2\}]\text{Cl(NO}_3)$ , have been prepared and characterised based on elemental analyses, IR, Raman, mass and  $^1\text{H}$  NMR spectral measurements. For the trinuclear complexes, the synthesis has been carried out using a step-up method branching out from the central palladium unit. A purity of about 95% has been obtained by repeated dissolution and precipitation. The activity against human cancer cell lines including ovary cell lines: A2780, A2780<sup>cisR</sup>, A2780<sup>ZD0473R</sup>, non small lung cell line: NCI-H640 and melanoma: Me-10538 have been determined based on MMT assay. Cell uptakes, DNA-binding have been determined for ovary cell lines: A2780, A2780<sup>cisR</sup>. The nature of interaction with pBR322 plasmid DNA and ssDNA has been studied for trinuclear complexes DH4Cl, DH5Cl, DH6Cl and DH7Cl and the dinuclear complex DHD. Interaction of DH6Cl with adenine and guanine has also been studied by HPLC. The compounds are found to exhibit significant anticancer activity against cancer cell lines especially ovarian cancer cell lines: A2780, A2780<sup>cisR</sup> and A2780<sup>ZD0473R</sup>. DH6Cl in which the linking diamine has six carbon atoms is found to be the most active compound. As the number of carbon atoms in the



linking diamine is changed from the optimum value of six, the activity is found to decrease, illustrating the structure-activity relationship. The increase in uptake of the trinuclear complexes in A2780 cell line with the increase in size of the linking diamine coupled with the low molar conductivity values found for the solutions of the compounds suggest that the compounds would remain in solution as undissociated 'molecules' and hence could cross the cell membrane by passive diffusion. Much lower resistance factors for the all the multinuclear compounds including DHD as applied to A2780<sup>cisR</sup> cell line, as compared to that for cisplatin, suggest that the compounds are able to overcome multiple mechanisms of resistance operating in the cell line. All of the multinuclear complexes are expected to form long-range interstrand GG adducts with DNA, causing irreversible global changes in the DNA conformation but unlike cisplatin do not cause sufficient DNA bending to be recognized by HMG 1 protein. Increasing prevention of BamH1 digestion with the increase in concentration of the multinuclear compounds also provide support to the idea that the compounds because of the formation of a plethora of interstrand GG adducts are able to cause irreversible changes in DNA conformation. The results of the study show that indeed new trinuclear tumour active compounds can be found by replacing the central platinum unit in BBR3464 with other suitable metal units.

## LIST OF FIGURES

Figure 1. 1 Representation of a nucleotide .....	9
Figure 1. 2 Structures of purine and pyrimidine .....	9
Figure 1. 3 The structures of adenine (A), guanine (G), thymine (T) and cytosine (C).....	10
Figure 1. 4 Representation of a polynucleotide chain.....	11
Figure 1. 5 The hydrogen bonding, between adenine and thymine, and between guanine and cytosine. ....	12
Figure 1. 6 Representation of double helical DNA.....	13
Figure 1. 7 The thirty highlighted elements believed essential to life (Bowser 1993) .....	15
Figure 2. 1 Structures of cisplatin and transplatin .....	21
Figure 2. 2 Bifunctional adducts on DNA of cisplatin (top) and transplatin (bottom) [Based on (Farrell 1996)].....	23
Figure 2. 3 Hydrolysis of cisplatin in aqueous solution.[Based on Berners-Price et al and El-Khateeb et al (El-Khateeb <i>et al.</i> 1999; Berners-Price and Appleton 2000)] .....	25
Figure 2. 4 Hydrogen bonding stabilization in guanine and destabilization in adenine .....	26
Figure 2. 5 Structure of carboplatin .....	34
Figure 2. 6 Chemical structures of cisplatin analogues in clinical trial.....	36
Figure 2. 7 Chemical structures of MJ335 and the orally active compounds MJ216, AMD473 and C5-OHP-Cl.....	40
Figure 2. 8 Summary of the ICR/JM platinum drug program from carboplatin to ZD0473(Based on Kelland (Kelland 2000a)) .....	43
Figure 2. 9 Structures of different classes of dinuclear Pt(II) complexes and the trinuclear compound BBR3464.....	46
Figure 3. 1. Scheme for the synthesis of DH6Cl (Only the tetrapositive cation of DH6Cl is shown in the scheme, the valencing anions namely 4Cl are not shown). ....	63
Figure 3. 2. Scheme for the synthesis of DH4Cl (Only the tetrapositive cation of DH4Cl is shown in the scheme, the valencing anions namely 4Cl are not shown). ....	65

Figure 3. 3	Scheme showing the steps in the synthesis of DH5Cl (Only the tetrapositive cation of DH5Cl is shown in the scheme, the valencing anions namely 4Cl are not shown).....	67
Figure 3. 4	Scheme showing the steps in the synthesis of DHD (Only the dipositive cation of DHD is shown in the scheme, the valencing anions namely Cl and NO <sub>3</sub> <sup>-</sup> are not shown). .....	71
Figure 3. 5	Typical standards addition graph for platinum.....	81
Figure 3. 6	Typical standards addition graph for palladium.....	81
Figure 3. 7	Migration of the three forms of plasmid DNA in gel.....	100
Figure 3. 8	Schematic presentation of the unwinding of supercoiled plasmid DNA from negatively supercoiled form I through relaxed circular form to positively supercoiled form I.....	102
Figure 4. 1	Structure of DH4Cl.....	108
Figure 4. 2	Structure of DH5Cl.....	109
Figure 4. 3	Structure of DH6Cl.....	110
Figure 4. 4	Structure of DH7Cl.....	111
Figure 4. 5	Structure of DHD.....	112
Figure 4. 6	Structure of DH1Cl.....	113
Figure 4. 7	IR spectrum of DH4Cl.....	115
Figure 4. 8	Raman spectrum of DH4Cl.....	116
Figure 4. 9	Mass spectrum of DH4Cl.....	116
Figure 4. 10	<sup>1</sup> H NMR spectrum of DH4Cl.....	117
Figure 4. 11	IR spectrum of DH5Cl.....	118
Figure 4. 12	Raman spectrum of DH5Cl.....	118
Figure 4. 13	Mass spectrum of DH5Cl.....	119
Figure 4. 14	<sup>1</sup> H NMR spectrum of DH5Cl.....	120
Figure 4. 15	IR spectrum of DH6Cl.....	121
Figure 4. 16	Raman spectrum of DH6Cl.....	122
Figure 4. 17	Mass spectrum of DH6Cl.....	123
Figure 4. 18	<sup>1</sup> H NMR spectrum of DH6Cl.....	123

Figure 4. 19 IR spectrum of DH7Cl.....	124
Figure 4. 20 Raman spectrum of DH7Cl.....	125
Figure 4. 21 Mass spectrum of DH7Cl.....	126
Figure 4. 22 <sup>1</sup> H NMR spectrum of DH7Cl.....	126
Figure 4. 23 IR spectrum of DHD .....	127
Figure 4. 24 Raman spectrum of DHD .....	128
Figure 4. 25 Mass spectrum of DHD .....	129
Figure 4. 26 <sup>1</sup> H NMR spectrum of DHD .....	129
Figure 4. 27 Survival curve for the ovary cell line A2780 when treated with increasing concentrations of DH6Cl, DH1Cl and cisplatin. ....	132
Figure 4. 28 Survival curve for the ovary cell line A2780 <sup>cisR</sup> when treated with increasing concentrations of DH6Cl, DH1Cl and cisplatin .....	133
Figure 4. 29 Survival curve for the ovary cell line A2780 <sup>ZD0473R</sup> when treated with increasing concentrations of DH6Cl, DH1Cl and cisplatin .....	134
Figure 4. 30 Survival curve for melanoma cell line Me-10530 when treated with increasing concentrations of DH6Cl, DH1Cl and cisplatin .....	135
Figure 4. 31 Survival curve for the non small lung cell line NCI-H460 when treated with increasing concentrations of DH6Cl, DH1Cl and cisplatin .....	136
Figure 4. 32 Survival curve for the ovary cell line A2780 when treated with increasing concentrations of DH4Cl, DH5Cl and DH7Cl.....	138
Figure 4. 33 Survival curve for the ovary cell line A2780 <sup>cisR</sup> when treated with increasing concentrations of DH4Cl, DH5Cl and DH7Cl.....	139
Figure 4. 34 Survival curve for the ovary cell line A2780 <sup>ZD0473R</sup> when treated with increasing concentrations of DH4Cl, DH5Cl and DH7Cl.....	140
Figure 4. 35 Survival curve for the melanoma cell line Me-10538 when treated with increasing concentrations of DH4Cl, DH5Cl and DH7Cl.....	141
Figure 4. 36 Survival curve for the non small lung cell line NCI-H460 when treated with increasing concentrations of DH4Cl, DH5Cl and DH7Cl.....	142
Figure 4. 37 Survival curve for the cell lines: A2780, A2780 <sup>cisR</sup> , A2780 <sup>ZD0473R</sup> , NCI-H640 and Me-10538 treated with increasing concentrations of DHD. ....	144

Figure 4. 38 Pt cell uptake as nmol Pt per $2 \times 10^6$ cells in A2780 and A2780 <sup>cisR</sup> cells in 4 h as applied to cisplatin, DH4Cl, DH5Cl, DH6Cl, DH7Cl and DHD .....	150
Figure 4. 39 Pt cell uptake in A2780 and A2780 <sup>cisR</sup> at 2 h and 4 h as applied to DH4Cl, DH6Cl and cisplatin .....	151
Figure 4. 40 Pd cell uptake as nmol Pd per $2 \times 10^6$ cells in A2780 and A2780 <sup>cisR</sup> cells in 4 h as applied to DH4Cl, DH5Cl, DH6Cl, DH7Cl and DHD .....	152
Figure 4. 41 Level of Pt-DNA binding expressed as nmol Pt per mg of DNA in A2780 and A2780 <sup>cisR</sup> cells in 4 h as applied to cisplatin, DH4Cl, DH5Cl, DH6Cl, DH7Cl and DHD .....	155
Figure 4. 42 Pt-DNA binding in A2780 and A2780 <sup>cisR</sup> in 2 h and 4 h as applied to cisplatin, DH6Cl and in A2780 as applied to DH4Cl .....	156
Figure 4. 43 Electrophoretograms applying to the interaction of pBR322 plasmid DNA with increasing concentrations of (a) DH4Cl, (b) DH5Cl, (c) DH6Cl, (d) DH7Cl, (e) DHD and (f) cisplatin .....	158
Figure 4. 44 Electrophoretograms applying to the incubated mixtures of pBR322 plasmid DNA and varying concentrations of compounds: (a) DH4Cl, (b) DH5Cl, (c) DH6Cl, (d) DH7Cl, (e) DHD and (f) cisplatin, followed by their digestion with BamH1.....	161
Figure 4. 45 Electrophoretograms applying to the interaction of ssDNA with increasing concentrations of (a) DH4Cl, (b) DH5Cl, (c) DH6Cl, (d) DH7Cl, (e) DHD and (f) cisplatin .....	164
Figure 5. 1 The IC <sub>50</sub> values, cell uptake and DNA-binding of DH4Cl, DH5Cl, DH6Cl, DH7Cl and DHD relative to cisplatin as applied to the A2780 cell line .....	187
Figure 5. 2 The IC <sub>50</sub> values, cell uptake and DNA-binding of DH4Cl, DH5Cl, DH6Cl, DH7Cl and DHD relative to cisplatin as applied to the A2780 <sup>cisR</sup> cell line .....	188
Figure 5. 3 The change in molar conductivity values for solutions of polynuclear compounds with the change in concentration. ....	190
Figure 5. 4 Docking between DH6Cl and double-stranded DNA fragment d(GGGGGGCCCCCC) showing that DH6Cl cover a distance of over nine nucleotides .....	205

Figure 5. 5 Docking between DH5Cl and double-stranded DNA fragment  
d(GGGGGGCCCCC) showing that DH5Cl cover a distance of over eight nucleotides  
.....205

## LIST OF TABLES

Table 2. 1 Comparison of in vitro cytotoxicity of dinuclear and mononuclear platinum compounds in a human ovarian tumour panel <sup>a</sup> (Farrell <i>et al.</i> 1999).....	48
Table 2. 2 Cytotoxicity and antitumour activity of polynuclear platinum complexes in murine leukaemia sensitive (L1210) and resistant to cisplatin (L1210/ <i>cis</i> -DDP) and in LX-1 human tumour xenograft (data adapted from Farrell (Farrell 2000).....	51
Table 2. 3 Cytotoxicity of cisplatin and BBR3464 in human tumour cell lines with different p53 status or expression .....	53
Table 3. 1. Furnace operating conditions for the determination of platinum .....	75
Table 3. 2. Instrument parameters for the determination of platinum .....	76
Table 3. 3. Sampler parameters used in AAS to determine platinum .....	77
Table 3. 4. Furnace operating conditions for the determination of palladium.....	78
Table 3. 5. Instrument parameters for the determination of palladium .....	79
Table 3. 6. Sampler parameters used in AAS to determine palladium .....	80
Table 3. 7 Constituents of the medium (FCS/RPMI 1640) .....	87
Table 4. 1 The percentage composition of DH4Cl.....	109
Table 4. 2 The percentage composition of DH5Cl.....	110
Table 4. 3 The percentage composition of DH6Cl.....	111
Table 4. 4 The percentage composition of DH7Cl.....	112
Table 4. 5 The percentage composition of DHD .....	113
Table 4. 6 The percentage composition of DH1Cl.....	114
Table 4. 7 Selected mass and <sup>1</sup> H NMR spectral peaks for DH4Cl, DH5Cl, DH6Cl, DH7Cl and DHD .....	130
Table 4. 8 The cell survival rate as a percentage of the control for the ovary cell line A2780, when the cells were treated with DH6Cl, DH1Cl and cisplatin .....	132
Table 4. 9 The cell survival rate as a percentage of the control for the ovary cell line A2780 <sup>cisR</sup> , when the cells were treated with DH6Cl, DH1Cl and cisplatin.....	133

Table 4. 10	The cell survival rate as a percentage of the control for the ovary cell line A2780 <sup>ZD0473R</sup> when the cells were treated with DH6Cl, DH1Cl and cisplatin .....	134
Table 4. 11	The cell survival rate as a percentage of the control for the melanoma cell line Me-10538, when the cells were treated with DH6Cl, DH1Cl and cisplatin .....	135
Table 4. 12	The cell survival rate as a percentage of the control for non small lung cell line NCI-H460, when the cells were treated with DH6Cl, DH1Cl and cisplatin .....	136
Table 4. 13	The cell survival rate as a percentage of the control for the ovary cell line A2780, when the cells were treated with DH4Cl, DH5Cl and DH7Cl.....	138
Table 4. 14	The cell survival rate as a percentage of the control for the ovary cell line A2780 <sup>cisR</sup> , when the cells were treated with DH4Cl, DH5Cl and DH7Cl.....	139
Table 4. 15	The cell survival rate as a percentage of the control for the ovary cell line A2780 <sup>ZD0473R</sup> , when the cells were treated with DH4Cl, DH5Cl and DH7Cl.....	140
Table 4. 16	The cell survival rate as a percentage of the control for the melanoma cell line Me-10538, when the cells were treated with DH4Cl, DH5Cl and DH7Cl.....	141
Table 4. 17	The cell survival rate as a percentage of the control for the non small lung cell line NCI-H460, when the cells were treated with DH4Cl, DH5Cl and DH7Cl.....	142
Table 4. 18	The cell survival rate as a percentage of the control for the ovary cell lines A2780, A2780 <sup>cisR</sup> and A2780 <sup>ZD0473R</sup> , when the cells were treated with DHD and cisplatin .....	143
Table 4. 19	The cell survival rate as a percentage of the control for the non small lung cell line NCI-H640 and melanoma Me-10538, when the cells were treated with DHD and cisplatin .....	144
Table 4. 20	IC <sub>50</sub> values and resistance factors (RF) for DH4Cl, DH5Cl, DH6Cl, DH7Cl, DH1Cl, DHD and cisplatin against the cell lines: A2780, A2780 <sup>cisR</sup> , A2780 <sup>ZD0473R</sup> , Me-10538 and NCI-H640.....	145
Table 4. 21	IC <sub>90</sub> for DH4Cl, DH5Cl, DH6Cl and DH7Cl against the cell lines: A2780, A2780 <sup>cisR</sup> , A2780 <sup>ZD0473R</sup> , Me-10538 and NCI-H640.....	147
Table 4. 22	Pt cell uptake as nmol Pt per 2x10 <sup>6</sup> cells in 4 h in A2780 and A2780 <sup>cisR</sup> as applied to cisplatin, DH4Cl, DH5Cl, DH6Cl, DH7Cl and DHD .....	149
Table 4. 23	Pt cell uptake as nmol Pt per 2x10 <sup>6</sup> cells in A2780 and A2780 <sup>cisR</sup> in 2 h as applied to cisplatin, DH4Cl and DH6Cl.....	150



Table 4. 24 Pd cell uptake as nmol Pd per $2 \times 10^6$ cells in 4 h in A2780 and A2780 <sup>cisR</sup> as applied to DH4Cl, DH5Cl, DH6Cl, DH7Cl and DHD .....	152
Table 4. 25 Molar ratio of the platinum and palladium cell uptakes in A2780 and A2780 <sup>cisR</sup> for DH4Cl, DH5Cl, DH6Cl, DH7Cl and DHD .....	153
Table 4. 26 Level of Pt-DNA binding (expressed as nmol Pt per mg DNA ) in 4 h in A2780 and A2780 <sup>cisR</sup> cells as applied to cisplatin, DH4Cl, DH5Cl, DH6Cl, DH7Cl and DHD.....	155
Table 4. 27 Level of Pt-DNA binding in 2 h (expressed as nmol Pt per mg of DNA) in A2780 and A2780 <sup>cisR</sup> cells as applied to DH6Cl and cisplatin and in A2780 cells only as applied to DH4Cl.....	156
Table 4. 28 Bands observed in the incubated mixtures of pBR322 plasmid DNA and varying concentrations of DH4Cl, DH5Cl, DH6Cl, DH7Cl, DHD and cisplatin followed by BamH1 digestion.....	163
Table 4. 29 The retention times of the main peaks with the detector set at $\lambda = 260$ nm for the mixtures and the components.....	166
Table 4. 30 Pt : NB binding ratios of the major peaks in the incubated mixtures of DH6Cl with adenine and guanine.....	167

## ABBREVIATIONS

<b>TMN</b>	TMN system, TMN stands for Tumour, Nodes and Metastases
<b>DNA</b>	Deoxyribonucleic acid
<b>Cis-DDP</b>	<i>cis</i> -diamminedichloroplatinum(II) also called cisplatin
<b>Trans-DDP</b>	<i>trans</i> -diamminedichloroplatinum(II) also called transplatin
<b>GSH:</b>	Glutathione
<b>MT:</b>	Metallothionine
<b>HMG:</b>	High mobility group
<b>MMR:</b>	Mismatch repair
<b>DACH:</b>	1,2-diaminocyclohexane
<b>CBCD</b>	<i>cis</i> -diammine-1,1-cyclobutanedicarboxylateplatinum(II), also called carboplatin
<b>JM</b>	Johnson Matthey
<b>ICR</b>	Institute of Cancer Research
<b>JM216</b>	bis(acetato)ammine-dichloro(cyclohexylamine)platinum(IV)
<b>JM335</b>	<i>trans</i> -ammine(cyclohexylaminedichloro-dihydroxo)platinum(IV)
<b>ZD0473</b>	<i>cis</i> -amminedichloro(2-methylpyridine)platinum(II)
<b>BBR3464</b>	$[\{trans\text{-PtCl}(\text{NH}_3)_2\}_2\{\mu\text{-trans-Pd}(\text{NH}_3)_2(\text{NH}_2(\text{CH}_2)_6\text{NH}_2)_2\}]^{4+}$
<b>DH4Cl</b>	$[\{trans\text{-PtCl}(\text{NH}_3)_2\}_2\{\mu\text{-trans-Pd}(\text{NH}_3)_2\text{-}(\text{H}_2\text{N}(\text{CH}_2)_4\text{NH}_2)_2\}]_2\text{Cl}_4$
<b>DH5Cl</b>	$[\{trans\text{-PtCl}(\text{NH}_3)_2\}_2\{\mu\text{-trans-Pd}(\text{NH}_3)_2\text{-}(\text{H}_2\text{N}(\text{CH}_2)_5\text{NH}_2)_2\}]_2\text{Cl}_4$
<b>DH6Cl</b>	$[\{trans\text{-PtCl}(\text{NH}_3)_2\}_2\{\mu\text{-trans-Pd}(\text{NH}_3)_2\text{-}(\text{H}_2\text{N}(\text{CH}_2)_6\text{NH}_2)_2\}]_2\text{Cl}_4$
<b>DH7Cl</b>	$[\{trans\text{-PtCl}(\text{NH}_3)_2\}_2\{\mu\text{-trans-Pd}(\text{NH}_3)_2\text{-}(\text{H}_2\text{N}(\text{CH}_2)_7\text{NH}_2)_2\}]_2\text{Cl}_4$
<b>DHD</b>	$[\{trans\text{-PtCl}(\text{NH}_3)_2\}_2\{\mu\text{-}(\text{H}_2\text{N}(\text{CH}_2)_6\text{NH}_2)\}\{trans\text{-PdCl}(\text{NH}_3)_2\}]_2\text{Cl}(\text{NO}_3)$
<b>DMF</b>	Dimethyl formamide
<b>DMSO</b>	Dimethyl sulfoxide
<b>Et<sub>3</sub>N</b>	Triethyl amine
<b>EDTA</b>	Ethylenediaminetetraacetic acid
<b>dpzm</b>	4,4'-dipyrazolylmethane

<b>AAS</b>	Atomic absorption spectrophotometry
<b>IR</b>	Infrared
<b>NMR</b>	Nuclear magnetic resonance
<b>MTT</b>	3-[4,5-dimethylthiazol-2-yl]-diphenyl tetrazolium bromide
<b>FCS</b>	Fetal calf serum
<b>PBS</b>	Phosphate buffered saline
<b>Triton X-100</b>	t-Octylphenoxy polyethoxyethanol
<b>ssDNA</b>	Salmon sperm DNA
<b>AMP</b>	Adenosine-5'-monophosphate
<b>ri</b>	Molar ratio
<b>NB</b>	Nucleobase
<b>HPLC</b>	High performance liquid chromatography
<b>IC<sub>50</sub> or ID<sub>50</sub></b>	Concentration required to inhibit cell growth by 50% in cell culture
<b>IC<sub>90</sub></b>	Concentration required to inhibit cell growth by 90% in cell culture
<b>RF</b>	Resistant factor

